Lv3
390 积分 2024-10-22 加入
Increase recombinant antibody yields through optimizing vector design and production process in CHO cells
22小时前
已完结
The new frontier in CHO cell line development: From random to targeted transgene integration technologies
23小时前
已完结
Biologics for severe asthma and beyond
3个月前
已完结
DOP10 Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial
4个月前
已完结
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
4个月前
已完结
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
4个月前
已完结
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
4个月前
已完结
Macrophages in intestinal homeostasis and inflammatory bowel disease
4个月前
已完结
IBD disease-modifying therapies: insights from emerging therapeutics
4个月前
已完结
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
5个月前
已完结
皖公网安备34019202002308
